Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV infection

Liver International

Volumn 31, Issue 4, 2011, Pages 507-515

  Petta, Salvatore ^a   Cammà, Calogero ^a   Marco, Vito Di ^a   Macaluso, Fabio Salvatore ^a   Maida, Marcello ^a   Pizzolanti, Giuseppe ^a   Belmonte, Beatrice ^a   Cabibi, Daniela ^a   Stefano, Rosa Di ^a   Ferraro, Donatella ^a   Guarnotta, Carla ^a   Venezia, Giovanna ^a   Craxì, Antonio ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

HBV; HCV; Steatosis

Indexed keywords

HEPATITIS B(E) ANTIGEN;

ADULT; ARTICLE; BODY MASS; CHRONIC HEPATITIS; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE SEVERITY; FATTY LIVER; FEMALE; GENOTYPE; HEPATITIS B; HEPATITIS C; HUMAN; INSULIN RESISTANCE; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS;

ALANINE TRANSAMINASE; BIOPSY; BLOOD GLUCOSE; BODY MASS INDEX; ENZYME-LINKED IMMUNOSORBENT ASSAY; FATTY LIVER; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS C; HUMANS; IMMUNOASSAY; INSULIN; INSULIN RESISTANCE; ITALY; LIVER CIRRHOSIS; MALE; PREVALENCE; REGRESSION ANALYSIS; TRIGLYCERIDES;

EID: 79952480382     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2011.02453.x     Document Type: Article

References (61)

1. Petta S, Muratore C, Craxì A. Non alcoholic fatty liver disease pathogenesis: the present and the future. Dig Liv Dis 2009; 41: 615-25.
2. Camma C, Petta S. Insulin resistance in HCV mono-infected and in HIV/HCV co-infected patients: looking to the future. J Hepatol 2009; 50: 648-51.
3. Lonardo A, Adinolfi LE, Petta S, et al. Hepatitis C and diabetes: the inevitable coincidence? Expert Rev Anti Infect Ther 2009; 7: 293-308.
4. Cammà C, Bruno S, Di Marco V, et al. Insulin resistance is associated with steatosis in nondiabetic patients with genotype 1 chronic hepatitis C. Hepatology 2006; 43: 64-71.
5. Petta S, Camma C, Di Marco V, et al. Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection. Am J Gastroenterol 2008; 103: 1136-44.
6. Cammà C, Petta S, Di Marco V, et al. Insulin resistance is a risk factor for esophageal varices in hepatitis C virus cirrhosis. Hepatology 2009; 49: 195-203.
7. Romero-Gómez M, Del Mar Viloria M, Andrade RJ, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005; 128: 636-41.
8. Czaja AJ, Carpenter HA. Sensitivity, specificity, and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology 1993; 105: 1824-32.
9. Lefkowitch JH, Schif ER, Davis GL, et al. Pathological diagnosis of chronic hepatitis C: a multicenter comparative study with chronic hepatitis B. Gastroenterology 1993; 104: 595-603.
10. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Host- and disease-specific factors affecting steatosis in chronic hepatitis C. J Hepatol 1998; 29: 198-206.
11. Sanyal AJ, Contos MJ, Sterling RK, et al. Nonalcoholic fatty liver disease in patients with hepatitis C is associated with features of the metabolic syndrome. Am J Gastroenterol 2003; 98: 2064-71.
12. Rosario R, Ramakrishna B. Histopathological study of chronic hepatitis B and C: a comparison of two scoring systems. J Hepatol 2003; 38: 223-9.
13. Altlparmak E, Köklü S, Yallnklllc M, et al. Viral and host causes of fatty liver in chronic hepatitis B. World J Gastroenterol 2005; 11: 3056-9.
14. Gordon A, McLean CA, Pedersen JS, et al. Hepatic steatosis in chronic hepatitis B and C: predictors, distribution and effect on fibrosis. J Hepatol 2005; 43: 38-44.
15. Thomopoulos KC, Arvaniti V, Tsamantas AC, et al. Prevalence of liver steatosis in patients with chronic hepatitis B: a study of associated factors and of relationship with fibrosis. Eur J Gastroenterol Hepatol 2006; 18: 233-7.
16. Papatheodoridis GV, Chrysanthos N, Savvas S, et al. Diabetes mellitus in chronic hepatitis B and C: prevalence and potential association with the extent of liver fibrosis. J Viral Hepatit 2006; 13: 303-10.
17. Tsochatzis E, Papatheodoridis GV, Manesis EK, et al. Hepatic steatosis in chronic hepatitis B develops due to host metabolic factors: a comparative approach with genotype 1 chronic hepatitis C. Digest Liver Dis 2007; 39: 936-42.
18. Siagris D, Vafiadis G, Michalaki M, et al. Serum adiponectin in chronic hepatitis C and B. J Viral Hepat 2007; 14: 577-83.
19. Bondini S, Kallman J, Wheeler A, et al. Impact of non-alcoholic fatty liver disease on chronic hepatitis B. Liv Int 2007; 27: 607-11.
20. Cindoruk M, Karakan T, Unal S. Hepatic steatosis has no impact on the outcome of treatment in patients with chronic hepatitis B infection. J Clin Gastroenterol 2007; 41: 513-7.
21. Elloumi H, Hefaiedh R, Gargouri D, et al. Hepatic steatosis in chronic hepatitis B: contributing factors and effect on fibrosis. Tunis Med 2008; 86: 1000-3.
22. Yun JW, Cho YK, Park JH, et al. Hepatic steatosis and fibrosis in young men with treatment-naïve chronic hepatitis B. Liv Int 2009; 29: 878-83.
23. Peng D, Han Y, Ding H, Wei L. Hepatic steatosis in chronic hepatitis B patients is associated with metabolic factors more than viral factors. J Gastroenterol Hepatol 2008; 23: 1082-8.
24. Shi J, Fan J, Wu R, et al. Prevalence and risk factors of hepatic steatosis and its impact on liver injury in Chinese patients with chronic hepatitis B infection. J Gastroenterol Hepatol 2008; 23: 1419-25.
25. Persico M, Masarone M, La Mura V, et al. Clinical expression of insulin resistance in hepatitis C and B virus-related chronic hepatitis: differences and similarities. World J Gastroenterol 2009; 15: 462-6.
26. Kumar M, Choudhury A, Manglik N, et al. Insulin resistance in chronic hepatitis B virus infection. Am J Gastroenterol 2009; 104: 76-82.
27. Minakari M, Molaei M, Shalmani HM, et al. Liver steatosis in patients with chronic hepatitis B infection: host and viral risk factors. Eur J Gastroenterol Hepatol 2009; 21: 512-6.
28. Park SH, Kim DJ, Lee HY. Insulin resistance is not associated with histologic severity in nondiabetic, noncirrhotic patients with chronic hepatitis B virus infection. Am J Gastroenterol 2009; 104: 1135-9.
29. Tsochatzis E, Papatheodoridis GV, Hadziyannis E, et al. Serum adipokine levels in chronic liver diseases: association of resistin levels with fibrosis severity. Scand J Gastroenterol 2008; 43: 1128-36.
30. Tsochatzis E, Papatheodoridis GV, Manolakopoulos S, et al. Smoking is associated with steatosis and severe fibrosis in chronic hepatitis C but not B. Scand J Gastroenterol 2009; 18: 1-8.
31. Wong VW, Wong GL, Yu J, et al. Interaction of adipokines and hepatitis B virus on histological liver injury in the Chinese. Am J Gastroenterol 2010; 105: 132-8.
32. Mellen JS, Xia VW, Hashemzadeh M, et al. The clinical presentation of chronic hepatitis B virus (HBV) infection in Asian Americans: a single center retrospective study. J Clin Gastroenterol 2010; 44: 364-70.
33. Imazeki F, Yokosuka O, Fukai K, et al. Prevalence of diabetes mellitus and insulin resistance in patients with chronic hepatitis C: comparison with hepatitis B virus-infected and hepatitis C virus-cleared patients. Liver Int 2008; 28: 355-62.
34. Moucari R, Asselah T, Cazals-Hatem D, et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 2008; 134: 416-23.
35. Targher G, Bertolini L, Padovani R, et al. Differences and similarities in early atherosclerosis between patients with non-alcoholic steatohepatitis and chronic hepatitis B and C. J Hepatol 2007; 46: 1126-32.
36. Wang C, Hsu C, Liu C, et al. Association of chronic hepatitis B virus infection with insulin resistance and hepatic steatosis. J Gastroenterol Hepatol 2008; 23: 779-82.
37. Wong G, Wong V, Choi P, et al. Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B. Gut 2009; 58: 111-7.
38. American Diabetes Association. Report of the expert committee on the diagnosis and classification of diabetes mellitus. American Diabetes Association: clinical practice recommendations 2000--committee report. Diabetes Care 2000; 23: S4-S19.
39. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-9.
40. Ikeda Y, Suehiro T, Nakamura T, et al. Clinical significance of the insulin resistance index as assessed by homeostasis model assessment. Endocr J 2001; 48: 81-6.
41. Bugianesi E, Pagotto U, Manini R, et al. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab 2005; 90: 3498-504.
42. Colloredo G, Guido M, Sonzogni A, Leandro G. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol 2003; 39: 239-44.
43. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991; 13: 372-4.
44. SAS Institute Inc. SAS Technical Report, SAS/STAS Software: Changes & Enhancement, Release 6.07. Cary, NC: SAS Institute Inc., 1992.
45. Adinolfi LE, Gambardella M, Andreana A, et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33: 1358-64.
46. Petta S, Cammà C, Di Marco V, et al. Retinol-binding protein 4: a new marker of virus-induced steatosis in patients infected with hepatitis c virus genotype 1. Hepatology 2008; 48: 28-37.
47. Bedogni G, Miglioli L, Masutti F, et al. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005; 42: 44-52.
48. Castera L, Hezode C, Roudot-Thoraval F, et al. Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis. Gut 2004; 53: 420-4.
49. Mihm S, Fayyazi A, Hartmann H, et al. Analysis of histopathological manifestations of chronic hepatitis C virus infection with respect to virus genotype. Hepatology 1997; 25: 735-9.
50. Leandro G, Mangia A, Hui J, et al. HCV meta-analysis (on) individual patients' data study group. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 2006; 130: 1636-42.
51. Rubbia-Brandt L, Quadri R, Abid K, et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol 2000; 33: 106-15.
52. Fartoux L, Poujol-Robert A, Guéchot J, et al. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut 2005; 54: 1003-8.
53. Bugianesi E, Marchesini G, Gentilcore E, et al. Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: role of insulin resistance and hepatic steatosis. Hepatology 2006; 44: 1648-55.
54. Kumar D, Farrell GC, Fung C, et al. Hepatitis C virus genotype 3 is cytopathic to hepatocytes: reversal of hepatic steatosis after sustained therapeutic response. Hepatology 2002; 36: 1266-72.
55. Kim K, Kim KH, Kim HH, Cheong J. Hepatitis B virus X protein induces lipogenic transcription factor SREBP1 and fatty acid synthase through the activation of nuclear receptor LXR alpha. Biochem J 2008; 416: 219-30.
56. Kim K, Shin H, Kim K, et al. Hepatitis B virus X protein induces hepatic steatosis via transcriptional activation of SREBP1 and PPARγ. Gastroenterology 2007; 132: 1955-67.
57. Na T, Shin Y, Roh K, et al. Liver X receptor mediates hepatitis B virus X protein-induced lipogenesis in hepatitis B virus-associated hepatocellular carcinoma. Hepatology 2009; 49: 1122-31.
58. Wang CS, Wang ST, Yao WJ, et al. Hepatitis C virus infection and the development of type 2 diabetes in a community-based longitudinal study. Am J Epidemiol 2007; 166: 196-203.
59. Mommeja-Marin H, Mondou E, Blum MR, et al. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. Hepatology 2003; 37: 1309-19.
60. Ticehurst JR, Hamzeh FM, Thomas DL. Factors affecting serum concentrations of hepatitis C virus (HCV) RNA in HCV genotype 1-infected patients with chronic hepatitis. J Clin Microbiol 2007; 45: 2426-33.
61. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004; 114: 147-52.